<span item_type="fundamental" item_id="a557ef914a0e4ea46f69c661e6fcf7bf" counter_id="ST/US/CTOR" env="prod"></span><span item_type="announcement" item_id="648746201417975297" env="prod"></span><p>Revenue: As of FY2026 Q2, the actual value is USD 1.667 M.</p><p>EPS: As of FY2026 Q2, the actual value is USD -0.27.</p><p>EBIT: As of FY2026 Q2, the actual value is USD -28.62 M.</p><p></p><h4>Overview</h4><p>Citius Oncology, Inc. reported $5.6 million in net revenue for the first half of fiscal 2026, with the LYMPHIR® launch progressing. The company secured up to $36.5 million in debt and equity capital. Broad payer coverage has been established with no reimbursement denials, and 83% of target accounts are either on formulary or under review <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</p><h4>Revenue</h4><ul><li>Net Product Revenues for the three months ended March 31, 2026, were $1.7 million, compared to no revenue for the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Net Product Revenues for the six months ended March 31, 2026, were $5.6 million, compared to no revenue for the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Gross Profit</h4><ul><li>Gross Profit for the three months ended March 31, 2026, was $1.3 million, representing an 80% margin <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Gross Profit for the six months ended March 31, 2026, was $4.5 million, representing an 80% margin <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Operating Expenses</h4><ul><li>Research and Development (R&amp;D) Expenses for the three months ended March 31, 2026, were $1.1 million, a decrease of $2.0 million from $3.1 million for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>R&amp;D Expenses for the six months ended March 31, 2026, were $2.1 million, a decrease of $2.3 million from $4.4 million for the six months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>General and Administrative (G&amp;A) Expenses for the three months ended March 31, 2026, were $23.6 million, an increase of $21.4 million from $2.2 million for the three months ended March 31, 2025, primarily due to a $19.7 million one-time CMO contract cancellation charge <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>G&amp;A Expenses for the six months ended March 31, 2026, were $26.5 million, an increase of $21.9 million from $5.5 million for the six months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Stock-based Compensation Expense for the three months ended March 31, 2026, was $3.5 million, compared to $2.1 million for the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Stock-based Compensation Expense for the six months ended March 31, 2026, was $7.5 million, compared to $3.9 million for the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Other Income/Loss</h4><ul><li>A Gain on Sale of New Jersey Net Operating Losses of $1.76 million was reported <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Net Loss</h4><ul><li>Net Loss for the three months ended March 31, 2026, was - $26.6 million, compared to a net loss of - $7.7 million for the three months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Net Loss for the six months ended March 31, 2026, was - $32.1 million, compared to a net loss of - $14.4 million for the six months ended March 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Liquidity and Cash Flow</h4><ul><li>Cash and Cash Equivalents as of March 31, 2026, totaled $2.6 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Net Cash Used In Operating Activities for the six months ended March 31, 2026, was - $11.19 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Net Cash Used In Investing Activities for the six months ended March 31, 2026, was - $5.0 million, primarily due to license payments <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Net Cash Provided by Financing Activities for the six months ended March 31, 2026, was $14.89 million, mainly from net proceeds from the issuance of common stock <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Subsequent to quarter-end, the company secured up to $36.5 million in combined financing, including approximately $11.5 million in gross proceeds from warrant exercises and $10 million funded from a senior secured term loan facility, with up to an additional $15 million available subject to milestones <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Operational Metrics</h4><ul><li>The LYMPHIR launch shows 83% of target accounts have added LYMPHIR or are actively progressing it through formulary review, with near 100% payer coverage for commercial lives and no reimbursement denials <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Inventory stood at $22.7 million of finished goods and work-in-process as of March 31, 2026, to support anticipated commercial demand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li><li>Initial shipment of LYMPHIR to Europe has commenced as part of international distribution agreements across 19 markets <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</li></ul><h4>Outlook / Guidance</h4><p>Citius Oncology, Inc. expects its full commercial team to be deployed by mid-summer and possesses ample inventory for anticipated commercial demand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>. Following May 2026 financings, the company anticipates sufficient funds to operate through November 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>. The company is also evaluating new bulk drug substance suppliers, with a letter of intent for a new contract manufacturing organization expected by the end of June 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm"></span>.</p>

Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M